FDA approves Viridian's Lumvoa for thyroid eye disease, launching competition with Amgen's $1.9B Tepezza on efficacy and infusion burden.
The FDA approved Viridian Therapeutics’ thyroid eye disease drug veligrotug, kicking off a competition with Amgen’s blockbuster Tepezza.
Viridian’s drug, to be marketed as Lumvoa …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Viridian may have edge over Amgen in eye drug showdown, analysts argue
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease - Virid
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
FDA approves Lumvoa for thyroid eye disease
Look out, Amgen. Here comes Viridian with FDA nod for TED med Lumvoa
FDA grants priority review to Enspryng for thyroid eye disease
New Drug Approved for Thyroid Eye Disease
Europe's CHMP reverses endorsement of Amgen's Tavneos as FDA hearing looms
Ollin refuels with $330M to back pivotal tests of Vabysmo challenger
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
